Journal: Journal of Advanced Research
Article Title: NAT10 promotes osteoclastogenesis in inflammatory bone loss by catalyzing Fos mRNA ac4C modification and upregulating MAPK signaling pathway
doi: 10.1016/j.jare.2024.07.031
Figure Lengend Snippet: Inhibition of NAT10 represses RANKL-activated MAPK signaling pathway. (A) Western blotting and quantification analysis of p-NFκB p65 and NFκB p65 in DMSO or Remodelin (20 μM)-pretreated RAW264.7 cells after RANKL stimulation at the designated times (n = 4). (B) Western blotting and quantification analysis of p-ERK1/2, ERK1/2, p-JNK, JNK, p-p38 and p38 in DMSO or Remodelin (20 μM)-pretreated RAW264.7 cells after RANKL stimulation at the designated times (n = 4). (C) Western blotting and quantification analysis of p-ERK1/2, ERK1/2, p-JNK, and JNK in DMSO or Remodelin (20 μM)-pretreated BMDMs after RANKL stimulation at the designated times (n = 4). (D) Western blotting and quantification analysis of p-ERK1/2, ERK1/2, p-JNK, and JNK in shNC and sh Nat10 RAW264.7 cells after RANKL stimulation at the designated times (n = 4). (E) The SRE-Luc and AP-1-Luc activities in DMSO or Remodelin (20 μM)-pretreated RAW264.7 cells after RANKL stimulation for 1 h (n = 4). Data were shown in the form of mean ± SD, two-way ANOVA was performed with Bonferroni’s multiple comparisons test, and Mann-Whitney U test was performed for comparisons between two groups. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
Article Snippet: Primary antibodies against β-actin, p-NFκB p65, NFκB p65, p-ERK1/2, ERK1/2, p-JNK, JNK, p-p38, and p38 were from Cell Signaling Technology, NAT10 was from Abcam (Cambridge, UK), ACP5, c-Jun, and c-Fos were from Proteintech (Wuhan, China), and NFATc1 was from Santa Cruz (CA, USA).
Techniques: Inhibition, Western Blot, MANN-WHITNEY